Abstract
Although the MSH6 G39E polymorphism is considered to be a biomarker of hereditary nonpolyposis colorectal cancer (HNPCC), many studies have also found that it may be associated with increased risks of lung, breast, and pancreatic cancers, with inconsistent estimated risks. Here, we performed a comprehensive meta-analysis to assess the associations. We searched published literature from MEDLINE, EMBASE, and CNKI for eligible publications up to Dec. 5, 2013. The final meta-analysis included 10 published studies of 7,046 cases and 34,554 controls for MSH6 G39E. Overall, no significant association was detected between MSH6 G39E and cancer risk (GE + EE vs. GG: OR = 0.92, 95 % CI = 0.81–1.04). Further stratifications, however, showed the MSH6 G39E variant is associated with a decreased risk for cancer in population-based studies (GE + EE vs. GG: OR = 0.80, 95 % CI = 0.60–0.91), and in studies having utilizing large sample sizes (GE + EE vs. GG: OR = 0.87, 95 % CI = 0.85–0.99). No potential publication bias was found among studies. The present meta-analysis identified some statistical evidence for an association between the MSH6 G39E polymorphism and risk of cancer. However, this finding warrants additional validation in large and well-designed prospective studies in the future.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs13277-014-1798-z/MediaObjects/13277_2014_1798_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs13277-014-1798-z/MediaObjects/13277_2014_1798_Fig2a_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs13277-014-1798-z/MediaObjects/13277_2014_1798_Fig2b_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs13277-014-1798-z/MediaObjects/13277_2014_1798_Fig3_HTML.gif)
Similar content being viewed by others
References
Imyanitov EN, Togo AV, Hanson KP. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett. 2004;204:3–14.
Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: Xpc polymorphisms modify smoking-related risk. Cancer Epidemiol Biomarkers Prev. 2006;15:306–11.
Hu Z, Shao M, Yuan J, Xu L, Wang F, Wang Y, et al. Polymorphisms in DNA damage binding protein 2 (ddb2) and susceptibility of primary lung cancer in the Chinese: a case-control study. Carcinogenesis. 2006;27:1475–80.
Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, Chatterjee N, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.
Berndt SI, Platz EA, Fallin MD, Thuita LW, Hoffman SC, Helzlsouer KJ. Mismatch repair polymorphisms and the risk of colorectal cancer. International journal of cancer Journal international du cancer. 2007;120:1548–54.
Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, et al. Penetrance and expressivity of msh6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004;74:1262–9.
Cederquist K, Emanuelsson M, Wiklund F, Golovleva I, Palmqvist R, Gronberg H. Two Swedish founder msh6 mutations, one nonsense and one missense, conferring high cumulative risk of lynch syndrome. Clin Genet. 2005;68:533–41.
Kastrinos F, Syngal S. Recently identified colon cancer predispositions: Myh and msh6 mutations. Semin Oncol. 2007;34:418–24.
Jenkins MA. Role of msh6 and pms2 in the DNA mismatch repair process and carcinogenesis. Surg Oncol Clin N Am. 2009;18:625–36.
Wu X, Khalpey Z, Cascalho M. Cellular physiology of mismatch repair. Curr Pharm Des. 2004;10:4121–6.
Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, et al. Germline mutation of msh6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 1997;17:271–2.
Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res. 1999;59:5068–74.
Wu Y, Berends MJ, Mensink RG, Kem**a C, Sijmons RH, van Der Zee AG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with msh6 germline mutations. Am J Hum Genet. 1999;65:1291–8.
Curtin K, Samowitz WS, Wolff RK, Caan BJ, Ulrich CM, Potter JD, et al. Msh6 g39e polymorphism and CpG island methylator phenotype in colon cancer. Mol Carcinog. 2009;48:989–94.
Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 2008;29:2132–8.
Dong X, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012;51:491–9.
Conde J, Silva SN, Azevedo AP, Teixeira V, Pina JE, Rueff J, et al. Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. BMC Cancer. 2009;9:344.
Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, et al. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res. 2006;66:11062–9.
Tulupova E, Kumar R, Hanova M, Slyskova J, Pardini B, Polakova V, et al. Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer? Mutat Res. 2008;648:40–5.
Picelli S, Zajac P, Zhou XL, Edler D, Lenander C, Dalen J, et al. Common variants in human CRC genes as low-risk alleles. Eur J Cancer. 2010;46:1041–8.
Shea B, Wells GA, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. 2011: www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed February 17, 2014.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315:629–34.
Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;58:661–7.
Nicolaides NC, Palombo F, Kinzler KW, Vogelstein B, Jiricny J. Molecular cloning of the n-terminus of GTBP. Genomics. 1996;31:395–7.
Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPS: server and survey. Nucleic Acids Res. 2002;30:3894–900.
Ng PC, Henikoff S. Sift: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812–4.
Parc YR, Halling KC, Wang L, Christensen ER, Cunningham JM, French AJ, et al. Hmsh6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res. 2000;60:2225–31.
Samowitz WS, Curtin K, Wolff RK, Albertsen H, Sweeney C, Caan BJ, et al. The mlh1–93 g>a promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosom Cancer. 2008;47:835–44.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, Z., Kong, L., Yu, L. et al. Association between MSH6 G39E polymorphism and cancer susceptibility: a meta-analysis of 7,046 cases and 34,554 controls. Tumor Biol. 35, 6029–6037 (2014). https://doi.org/10.1007/s13277-014-1798-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-1798-z